CN112672762B - 用于抗流感化学治疗和免疫治疗的小分子配体靶向药物缀合物 - Google Patents

用于抗流感化学治疗和免疫治疗的小分子配体靶向药物缀合物 Download PDF

Info

Publication number
CN112672762B
CN112672762B CN201980056374.6A CN201980056374A CN112672762B CN 112672762 B CN112672762 B CN 112672762B CN 201980056374 A CN201980056374 A CN 201980056374A CN 112672762 B CN112672762 B CN 112672762B
Authority
CN
China
Prior art keywords
zanamivir
conjugate
cells
influenza
infected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980056374.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112672762A (zh
Inventor
菲利普·斯图尔特·罗吾
刘鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of CN112672762A publication Critical patent/CN112672762A/zh
Application granted granted Critical
Publication of CN112672762B publication Critical patent/CN112672762B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201980056374.6A 2018-07-26 2019-07-20 用于抗流感化学治疗和免疫治疗的小分子配体靶向药物缀合物 Active CN112672762B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862703534P 2018-07-26 2018-07-26
US62/703,534 2018-07-26
US201962846549P 2019-05-10 2019-05-10
US62/846,549 2019-05-10
PCT/US2019/042715 WO2020023323A1 (en) 2018-07-26 2019-07-20 Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy

Publications (2)

Publication Number Publication Date
CN112672762A CN112672762A (zh) 2021-04-16
CN112672762B true CN112672762B (zh) 2025-06-13

Family

ID=69180703

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980056374.6A Active CN112672762B (zh) 2018-07-26 2019-07-20 用于抗流感化学治疗和免疫治疗的小分子配体靶向药物缀合物

Country Status (7)

Country Link
US (2) US20210393786A1 (cg-RX-API-DMAC7.html)
EP (1) EP3826681A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021531312A (cg-RX-API-DMAC7.html)
CN (1) CN112672762B (cg-RX-API-DMAC7.html)
AU (1) AU2019312144B2 (cg-RX-API-DMAC7.html)
CA (1) CA3107778A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020023323A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022008901A (es) 2020-01-24 2022-08-16 Regeneron Pharma Conjugados de proteinas-compuestos antivirales.
US20210402001A1 (en) * 2020-06-30 2021-12-30 David I. Cohen Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers
US20230312562A1 (en) * 2020-07-02 2023-10-05 Purdue Research Foundation Tetrahydro-3h-pyrazolo quinolone and tetrahydro-3h-pyrrolo[3,2-f]quinoline -containing compounds and uses thereof
EP4178626A4 (en) * 2020-07-13 2024-08-14 University of Southern California Universal car-nk cell targeting various epitopes of hiv-1 gp160
EP4337663A4 (en) * 2021-05-14 2026-04-15 Purdue Research Foundation BISPECIFIC SMALL MOLECULE-BASED IMMUNE CELL ATTACHMENTS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION
KR20240038928A (ko) * 2021-07-28 2024-03-26 리제너론 파마슈티칼스 인코포레이티드 단백질-항바이러스 화합물 접합체
IL316372A (en) * 2022-04-19 2024-12-01 Purdue Research Foundation Double and triple hapten conjugatively coupled double and triple hapten, preparations, manufacturing processes and methods of handling them
CN116375647A (zh) * 2023-01-21 2023-07-04 兰州大学 一种基于Click反应的CAR-T细胞药物递送平台及其构建方法与应用
WO2025085664A1 (en) * 2023-10-17 2025-04-24 Mary Lynn Niedrauer Conjugates, com positions and methods for treating influenza
WO2025133395A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Bicyclic (hetero)arylene wrn inhibitory compounds
WO2026044019A1 (en) * 2024-08-21 2026-02-26 Low Stewart Compositions and methods for treating influenza infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102036658A (zh) * 2008-05-23 2011-04-27 香港大学 治疗流感的联合疗法
CN103068378A (zh) * 2010-05-10 2013-04-24 中央研究院 具有抗流感活性的扎那米韦膦酸酯同类物及流感病毒的奥司他韦易感性的测定

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6692724B1 (en) * 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
IL153218A0 (en) * 2000-06-02 2003-07-06 Univ Texas Ethylenedicysteine (ec) -drug conjugates
WO2002044324A2 (en) * 2000-10-06 2002-06-06 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
CA2790577A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
AU2011314335A1 (en) * 2010-06-25 2013-01-31 Purdue Research Foundation Pathogen detection
US10130714B2 (en) * 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
EP2934532B1 (en) * 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US10975112B2 (en) * 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
CA3019835A1 (en) * 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102036658A (zh) * 2008-05-23 2011-04-27 香港大学 治疗流感的联合疗法
CN103068378A (zh) * 2010-05-10 2013-04-24 中央研究院 具有抗流感活性的扎那米韦膦酸酯同类物及流感病毒的奥司他韦易感性的测定

Also Published As

Publication number Publication date
WO2020023323A1 (en) 2020-01-30
EP3826681A1 (en) 2021-06-02
US20260144880A1 (en) 2026-05-28
EP3826681A4 (en) 2022-08-17
CA3107778A1 (en) 2020-01-30
CN112672762A (zh) 2021-04-16
US20210393786A1 (en) 2021-12-23
JP2021531312A (ja) 2021-11-18
AU2019312144A1 (en) 2021-03-18
JP2024029005A (ja) 2024-03-05
AU2019312144B2 (en) 2025-05-08

Similar Documents

Publication Publication Date Title
AU2019312144B2 (en) Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy
RU2769317C2 (ru) Способы лечения гриппа
Hendricks et al. Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza A virus
Dong et al. γδ T cells provide protective function in highly pathogenic avian H5N1 influenza A virus infection
JP2013538564A (ja) 抗ウイルス剤
Hoffmann et al. A new class of synthetic anti-lipopolysaccharide peptides inhibits influenza A virus replication by blocking cellular attachment
Lin et al. Potent influenza A virus entry inhibitors targeting a conserved region of hemagglutinin
CA2787940C (en) Engineered polypeptide agents for targeted broad spectrum influenza neutralization
Tian et al. Dihydromyricetin is a new inhibitor of influenza polymerase PB2 subunit and influenza-induced inflammation
Hussein et al. Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus
Wu et al. New influenza A virus entry inhibitors derived from the viral fusion peptides
Xu et al. Inhibition of peptide BF-30 on influenza A virus infection in vitro/vivo by causing virion membrane fusion
Lv et al. Zanamivir–cholesterol conjugate: a long-acting neuraminidase inhibitor with potent efficacy against drug-resistant influenza viruses
CN104151403A (zh) 一类多肽或其衍生物、及其在流感病毒感染中的应用
Chen et al. The seafood Musculus senhousei shows anti-influenza A virus activity by targeting virion envelope lipids
Yang et al. Influenza virus entry inhibitors
Wu et al. Super short membrane-active lipopeptides inhibiting the entry of influenza A virus
Sriwilaijaroen et al. 6SLN-lipo PGA specifically catches (coats) human influenza virus and synergizes neuraminidase-targeting drugs for human influenza therapeutic potential
Liu et al. Design of neuraminidase-targeted imaging and therapeutic agents for the diagnosis and treatment of influenza virus infections
Lin et al. A “building block” approach to the new influenza A virus entry inhibitors with reduced cellular toxicities
HK40050842A (en) Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy
HK40050842B (en) Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy
Liu Small Molecule Ligand-Targeted Delivery of Therapeutic Agents for Treatment of Influenza Virus Infections
WO2026044019A1 (en) Compositions and methods for treating influenza infection
US20180264128A1 (en) Compounds for medicinal applications

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050842

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant